Uncategorized
Speaker: Data support use of ranibizumab treatment for diabetic retinopathy
KOLOA, Hawaii – Data suggest that a delay in ranibizumab therapy “results in a reduction in the chance to improve the diabetic retinopathy severity level,” a speaker said here, but stopped short of recommending it. Using data from the RIDE and RISE trials, Michael S. Ip, MD, of the University of Wisconsin, and colleagues examined the state of progression of diabetic retinopathy in ranibizumab-treated. Diabetic retinopathy severity was found to be less likely to worsen and more likely to improve in eyes treated with continued therapy of ranibizumab.